Traders should consider this a positive catalyst given the combination of commercial launch and 7-year market exclusivity in a high-unmet-need pediatric population. The exclusivity reduces near-term competitive risk and supports premium pricing and reimbursement. Monitor sales ramp in upcoming quarters as a key indicator of uptake.
Price Chart
Executive Summary
Ascendis Pharma announced that YUVIWEL (navepegritide), its once-weekly treatment for children with achondroplasia, has been granted orphan drug exclusivity by the FDA and is now commercially available in the United States. The exclusivity extends through February 27, 2033, providing market protection for this first-in-class therapy.
Key Facts
- YUVIWEL (navepegritide) received orphan drug exclusivity from the FDA
- YUVIWEL is now commercially available in the U.S.
- It is the first and only once-weekly treatment approved to increase linear growth in children 2 years and older with achondroplasia
- Orphan drug exclusivity runs through February 27, 2033
- The drug provides continuous systemic exposure to CNP over the weekly dosing interval
Financial Impact
Significant long-term revenue potential due to market exclusivity and first-mover advantage in a rare disease indication
Risk Factors
- Market acceptance and reimbursement challenges
- Dependence on third-party manufacturers and supply chain
- Potential safety or efficacy findings post-launch
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001193125-26-144463 |
| Document: 0001193125-26-144463-index-headers.html | 0001193125-26-144463 |
| Document: 0001193125-26-144463-index.html | 0001193125-26-144463 |
| Document: 0001193125-26-144463.txt | 0001193125-26-144463 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 9, 2026 23d ago | Insider Cluster | $260.81 $247.69 | ▼ −5.03% | ▼ −4.37% | $227.23 (−12.88%) |
Aug 31, 2026 4w ago | 6-K | $260.25 $260.81 | ▲ +0.22% | ▲ +0.13% | $227.23 (−12.69%) |
Aug 27, 2026 5w ago | ANALYST-UPGRADE | $249.36 $271.12 | ▲ +8.73% | ▲ +8.46% | $227.23 (−8.87%) |
Aug 19, 2026 6w ago | ANALYST-UPGRADE | $259.62 $250.25 | ▼ −3.61% | ▼ −3.22% | $227.23 (−12.48%) |
Aug 19, 2026 6w ago | Insider Buy | $259.62 $250.25 | ▼ −3.61% | ▼ −3.22% | $227.23 (−12.48%) |
Aug 13, 2026 7w ago | 6-K | $246.23 $254.81 | ▲ +3.48% | ▲ +5.45% | $227.23 (−7.72%) |
Aug 13, 2026 7w ago | Press Release | $246.23 $254.81 | ▲ +3.48% | ▲ +5.45% | $227.23 (−7.72%) |
Aug 6, 2026 8w ago | 6-K | $249.85 $246.23 | ▼ −1.45% | ▼ −2.66% | $227.23 (−9.05%) |
Aug 6, 2026 8w ago | Press Release | $249.85 $246.23 | ▼ −1.45% | ▼ −2.66% | $227.23 (−9.05%) |
Jul 15, 2026 11w ago | 6-K | $259.80 $252.66 | ▼ −2.75% | ▼ −1.08% | $227.23 (−12.54%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access